Clinical Trial Update: Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study comparing BI 6727 (volasertib) alone and in combination with pemetrexed versus pemetrexed alone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)
• Volasertib (Volasertib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2016-09-20